排序方式: 共有33条查询结果,搜索用时 31 毫秒
1.
Impact of Obesity on Quality of Life,Psychological Distress,and Coping on Patients with Colon Cancer
David Gomez Paula Jimenez-Fonseca Aránzazu Manzano Fernández Patricia Cruz Castellanos Maria Valero Arbizu Ruth Martínez Cabañes David Lorente Estellés Estrella Ferreira Jorge del Rio Teresa García García Alberto Carmona-Bayonas Caterina Calderon 《The oncologist》2021,26(5):e874-e882
BackgroundDespite the causal relationship between obesity and colon cancer being firmly established, the effect of obesity on the course of cancer calls for further elucidation. The objective of this study was to assess differences in clinical‐pathological and psychosocial variables between obese and nonobese individuals with colon cancer.Materials and MethodsThis was a prospective, multicentric, observational study conducted from 2015–2018. The sample comprised patients with stage II–III, resected colon cancer about to initiate adjuvant chemotherapy with fluoropyrimidine in monotherapy or associated with oxaliplatin and grouped into nonobese (body mass index <30 kg/m2) or obese (≥30 kg/m2). Subjects completed questionnaires appraising quality of life (European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire), coping (Mini‐Mental Adjustment to Cancer), psychological distress (Brief Symptom Inventory 18), perceived social support (Multidimensional Scale of Perceived Social Support), personality (Big Five Inventory 10), and pain (Brief Pain Inventory). Toxicity, chemotherapy compliance, 12‐month recurrence, and mortality rate data were recorded.ResultsSeventy‐nine of the 402 individuals recruited (19.7%) were obese. Obese subjects exhibited more comorbidities (≥2 comorbidities, 46.8% vs. 30.3%, p = .001) and expressed feeling slightly more postoperative pain (small size‐effect). There was more depression, greater helplessness, less perceived social support from friends, and greater extraversion among the obese versus nonobese subjects (all p < .04). The nonobese group treated with fluoropyrimidine and oxaliplatin suffered more grade 3–4 hematological toxicity (p = .035), whereas the obese had higher rates of treatment withdrawal (17.7% vs. 7.7%, p = .033) and more recurrences (10.1% vs. 3.7%, p = .025). No differences in sociodemographic, quality of life, or 12‐month survival variables were detected.ConclusionObesity appears to affect how people confront cancer, as well as their tolerance to oncological treatment and relapse.Implications for PracticeObesity is a causal factor and affects prognosis in colorectal cancer. Obese patients displayed more comorbidities, more pain after cancer surgery, worse coping, and more depression and perceived less social support than nonobese patients. Severe hematological toxicity was more frequent among nonobese patients, whereas rates of withdrawal from adjuvant chemotherapy were higher in the obese cohort, and during follow‐up, obese patients presented greater 12‐month recurrence rates. With the growing and maintained increase of obesity and the cancers associated with it, including colorectal cancer, the approach to these more fragile cases that have a worse prognosis must be adapted to improve outcomes. 相似文献
2.
Alvarez-Manceñido Felipe Jimenez-Fonseca Paula Carmona-Bayonas Alberto Arrazubi Virginia Hernandez Raquel Cano Juana M. Custodio Ana Pericay Pijaume Carles Aguado Gema Martínez Lago Nieves Sánchez Cánovas Manuel Cacho Lavin Diego Visa Laura Martinez-Torron Alba Arias-Martinez Aranzazu López Flora Limón M. Luisa Vidal Tocino Rosario Fernández Montes Ana Alsina Maria Pimentel Paola Reguera Pablo Martín Carnicero Alfonso Ramchandani Avinash Granja Mónica Azkarate Aitor Martín Richard Marta Serra Olbia Hernández Pérez Carolina Hurtado Alicia Gil-Negrete Aitziber Sauri Tamara Morales del Burgo Patricia Gallego Javier 《Gastric cancer》2021,24(4):926-936
Gastric Cancer - Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical... 相似文献
3.
Paula Jiménez-Fonseca Alberto Carmona-Bayonas Maria Luisa Sánchez Lorenzo Javier Gallego Plazas Ana Custodio Raquel Hernández Marcelo Garrido Teresa García Isabel Echavarría Juana María Cano Alberto Rodríguez Palomo Monserrat Mangas Ismael Macías Declara Avinash Ramchandani Laura Visa Antonio Viudez Elvira Buxó Asunción Díaz-Serrano Carlos López Aitor Azkarate Federico Longo Eduardo Castañón Rodrigo Sánchez Bayona Paola Pimentel Maria Luisa Limón Paula Cerdá Renata Álvarez Llosa Raquel Serrano Maria Pilar Felices Lobera María Alsina Alicia Hurtado Nuño Carlos Gómez-Martin 《Gastric cancer》2017,20(3):465-474
Background
Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC.Methods
This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression.Results
The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001–1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2.Conclusion
Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.4.
A. Carmona-Bayonas P. Jiménez-Fonseca E. Castañón A. Ramchandani-Vaswani R. Sánchez-Bayona A. Custodio D. Calvo-Temprano J. A. Virizuela 《Clinical & translational oncology》2017,19(2):236-250
Purpose
Long-term cancer survivors develop special health issues and specific needs. Chronic pain, whether the consequence of their cancer or as a side effect of treatment, is one of their most prevalent concerns.Methods
We conducted a review of the English-language literature on long-term cancer survivorship and chronic opioid therapy, with the objective of determining the efficacy, safety and tolerability in this group of patients. Practical management recommendations are made on the basis of this review.Results
Pain syndromes encountered in the long-term cancer survivors are diverse. Opioid receptor pathways possess complex and pleiotropic functions and continuous over-activation may lead to de novo endocrinopathies, immunosuppression, neurocognitive impairment, or cell cycle disturbances with potential clinical connotations. However, there are insufficient data to support evidence-based decision making with respect to patient selection, doses, administration, monitoring and follow-up. Data about long-term treatment effectiveness and safety are limited and often aggravated by the overlapping of several diseases prevalent among long-term cancer survivors, as well as chronic opiate-induced toxicity.Conclusions
Chronic opioid therapy is frequent in long-term cancer survivors, and may negatively affect the immune system, and produce health problems such as endocrinopathies, osteoporosis, neurological or cardiopulmonary effects, alterations of cell cycle kinetics, abuse and addiction. This review highlights the need for specialized teams to treat chronic pain in long-term cancer survivors from an integrative perspective.5.
P. Jimenez-Fonseca A. Carmona-Bayonas C. Calderon J. Fontcuberta Boj C. Font R. Lecumberri M. Monreal A. J. Muñoz Martín R. Otero A. Rubio P. Ruiz-Artacho C. Suarez Fernández E. Colome P. Pérez Segura 《Clinical & translational oncology》2017,19(8):997-1009
Introduction
Decision-making in cancer-related venous thromboembolism (VTE) is often founded on scant lines of evidence and weak recommendations. The aim of this work is to evaluate the percentage of agreement surrounding a series of statements about complex, clinically relevant, and highly uncertain aspects to formulate explicit action guidelines.Materials and methods
Opinions were based on a structured questionnaire with appropriate scores and were agreed upon using a Delphi method. Questions were selected based on a list of recommendations with low evidence from the Spanish Society of Oncology Clinical Guideline for Thrombosis. The questionnaire was completed in two iterations by a multidisciplinary panel of experts in thrombosis.Results
Of the 123 statements analyzed, the panel concurred on 22 (17%) and another 81 (65%) were agreed on by qualified majority, including important aspects of long-term and prolonged anticoagulation, major bleeding and rethrombosis management, treatment in special situations, catheter-related thrombosis and thromboprophylaxis. Among them, the panelists agreed the incidental events should be equated to symptomatic ones, long-term and extended use of full-dose low-molecular weight heparin, and concluded that the Khorana score is not sensitive enough to uphold an effective thromboprophylaxis strategy.Conclusion
Though the level of consensus varied depending on the scenario presented, overall, the iterative process achieved broad agreement as to the general treatment principles of cancer-associated VTE. Clinical validation of these statements in genuine practice conditions would be useful.6.
A.?Carmona-Bayonas P.?Jiménez-Fonseca J.?Virizuela M.?Antonio C.?Font M.?Biosca A.?Ramchandani J.?Martinez-Garcia J.?Hernando J.?Espinosa E.?M.?de?Castro I.?Ghanem C.?Beato A.?Blasco M.?Garrido R.?Mondéjar M.?á.?Arcusa I.?Aragón A.?Manzano E.?Sevillano E.?Casta?ón F.?Ayala On behalf of the Supportive Care Working Group of the Spanish Society of Medical Oncology 《Clinical & translational oncology》2017,19(3):386-395
Purpose
The clinical index of stable febrile neutropenia (CISNE) can contribute to patient safety without increasing the complexity of decision-making. However, febrile neutropenia (FN) is a diverse syndrome. The aim of this analysis is to assess the performance of CISNE according to the type of tumor and infection and to characterize these patients.Methods
We prospectively recruited 1383 FN episodes in situations of apparent clinical stability. Bonferroni-adjusted z tests of proportions were used to assess the association between the infections suspected at the time of onset and the type of tumor with the risk of serious complications and mortality. The performance of CISNE was appraised in each category using the Breslow-Day test for homogeneity of odds ratios and Forest Plots.Results
171 patients had a serious complication (12.3 %, 95 % confidence interval 10.7–14.2 %). The most common initial assumptive diagnoses were: fever without focus (34.5 %), upper respiratory infection (14.9 %), enteritis (12.7 %), stomatitis (11.8 %), and acute bronchitis (10.7 %). Lung and breast were the most common tumors, accounting for approximately 56 % of the series. The distribution of complications, mortality, and bacteremia varies for each of these categories. However, Breslow-Day tests indicate homogeneity of the odds ratio of the dichotomized CISNE score to predict complications in all infection and tumor subtypes.Conclusion
Despite FN’s clinical and microbiological heterogeneity, the CISNE score was seen to be consistent and robust in spite of these variations. Hence, it appears to be a safe tool in seemingly stable FN.7.
C. Calderon P. J. Ferrando A. Carmona-Bayonas U. Lorenzo-Seva C. Jara C. Beato T. García A. Ramchandani B. Castelo M. M. Muñoz S. Garcia O. Higuera M. Mangas-Izquierdo P. Jimenez-Fonseca 《Clinical & translational oncology》2017,19(11):1312-1319
Objective
The aim of this study was to analyze the psychometric properties of the Shared Decision-Making Questionnaire–Physician version (SDM-Q-Doc) in a sample of medical oncologists who provide adjuvant treatment to patients with non-metastatic resected cancer and the correlations between the total SDM-Q-Doc score and physician satisfaction with the information provided.Methods
Prospective, observational and multicenter study in which 32 medical oncologists and 520 patients were recruited. The psychometric properties, dimensionality, and factor structure of the SDM-Q-Doc were assessed.Results
Exploratory factor analyses suggested that the most likely solution was two-dimensional, with two correlated factors: one factor regarding information and another one about treatment. Confirmatory factor analysis based on cross-validation showed that the fitted two-dimensional solution provided the best fit to the data. Reliability analyses revealed good accuracy for the derived scores, both total and sub-scale, with estimates ranging from 0.81 to 0.89. The results revealed significant correlations between the total SDM-Q-Doc score and physician satisfaction with the information provided (p < 0.01); between information sub-scale scores (factor 1) and satisfaction (p < 0.01), and between treatment sub-scale scores (factor 2) and satisfaction (p < 0.01). Medical oncologists of older age and those with more years of experience showed more interest in the patient preferences (p = 0.026 and p = 0.020, respectively). Patient age negatively correlated with SDM information (p < 0.01) and physicians appear to provide more information to young patients.Conclusion
SDM-Q-Doc showed good psychometric properties and could be a helpful tool that examines physician’s perspective of SDM and as an indicator of quality and satisfaction in patients with cancer.8.
P. Jimenez-Fonseca C. Calderon A. Carmona-Bayonas M. M. Muñoz R. Hernández M. Mut Lloret I. Ghanem C. Beato D. Cacho Lavín A. Ivars Rubio R. Carrión C. Jara 《Clinical & translational oncology》2018,20(11):1392-1399
Purpose
The aim of this study was to analyze differences in physician and patient satisfaction in shared decision-making (SDM); patients’ emotional distress, and coping in subjects with resected, non-metastatic cancer.Methods
602 patients from 14 hospitals in Spain were surveyed. Information was collected regarding physician and patient satisfaction with SDM, participants’ emotional distress and coping, as well as patient sociodemographic and clinical characteristics by means of specific, validated questionnaires.Results
Overall, 11% of physicians and 19% of patients were dissatisfied with SDM; 22% of patients presented hopelessness or anxious preoccupation as coping strategies, and 56% presented emotional distress. By gender, female patients showed a higher prevalence of dissatisfaction with SDM (23 vs 14%), anxious preoccupation (26 vs 17%), and emotional distress (63 vs 44%) than males. Hopelessness was more prevalent in individuals with stage III disease than those with stages I–II (28 vs 18%).Conclusion
Physicians must be mindful of the importance of emotional support and individual characteristics when communicating treatment options, benefits, and adverse effects of each alternative to oncological patients.9.
M. M. Muñoz-Sánchez C. Calderon P. Jimenez-Fonseca M. C. Soriano-Rodríguez C. Jara T. García-García C. Beato J. Rogado B. Castelo R. Hernández M. Mangas-Izquierdo A. Carmona-Bayonas 《Clinical & translational oncology》2018,20(12):1604-1611
Purpose
Despite the burgeoning geriatric population with cancer and the importance of understanding how age may be related to mental adjustment and quality of life so far, differences in coping strategies and psychological harm between the elderly and adults are hardly being taken into account to modify the approach to this population. The aim of this prospective study is to describe the differences in psychological characteristics between older and adult cancer patients and examine dissimilarities in their psychological evolution during adjuvant chemotherapy.Methods
Adults (18–69 years old) and older patients (≥?70) with newly diagnosed non-metastatic resected cancer admitted to receive adjuvant chemotherapy were recruited. Patients completed the following questionnaires: mini-mental adjustment to cancer, brief symptom inventory, shared decision-making questionnaire–patient’s version, multidimensional scale of perceived social support, EORTC quality-of-life instrument, life orientation test-revised, and satisfaction with life scale.Results
500 cancer patients (394 adults and 106 older) were evaluated. The impact of the diagnosis was less negative among older patients, with no differences in coping strategies, quality of life, or search for support. Regarding psychological changes from the beginning to the end of the adjuvant treatment, both age groups reported more somatic symptoms, increased psychological difficulty, reduced coping strategies, and a significant decrease in quality of life at the end of postoperative chemotherapy.Conclusion
Although there were clear psychological differences between adults and senior cancer patients, their evolution during adjuvant chemotherapy was similar, with deterioration in quality of life and coping. This negative psychological impact of adjuvant chemotherapy should be taken into account when considering interventions.10.
Carmona-Bayonas A; Soler IO; Gomez FI; Billalabeitia EG; Saura HP; Tafalla MSA; Diaz MP 《Annals of oncology》2007,18(7):1281
Mitotane is often considered the front-line hormonal therapyof adrenocortical carcinoma (ACC). An illustrative case concerningthis issue and the rationale to ponder other alternatives isreported. A 69 year-old woman, diagnosed with ACC was admittedwith hypertensive crisis, supraventricular tachycardia, congestiveheart-failure, diarrhoea and rabdomyolisis. Two years earlier,she had undergone 相似文献